Albert P. P.
- Country
- Spain
- Department
- Unitat de deteriorament cognitiu i transtorns del moviment
Research Overview
- A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
- Efficacy and Safety Evaluation of Mirodenafil Dihydrochloride in Early Alzheimer's Disease: A Phase 3 Double-Blind, Randomized, Placebo-Controlled Trial
- Evaluation of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Early Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Data & Insights
Has run more than one trial at 17 of 86 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in studying early-stage Alzheimer's disease, with particular emphasis on innovative therapeutic approaches targeting disease progression.
- Tau protein-targeted therapies
- Anti-MTBR tau antibody treatments
- Novel therapeutic compounds
Their research focuses on evaluating cognitive function and disease progression through clinical assessment tools like the Clinical Dementia Rating Scale.
Clinical Assessment
The investigator conducts comprehensive evaluations of cognitive decline and functional capabilities in patients with early Alzheimer's disease.
- Cognitive function monitoring
- Disease progression markers
- Treatment response assessment
Their work involves measuring changes in thinking and general functioning over extended treatment periods.
Therapeutic Development
The investigator evaluates novel therapeutic interventions for early Alzheimer's disease, focusing on safety and efficacy assessments.
- Disease-modifying treatments
- Therapeutic safety profiles
- Clinical efficacy measures
Their research encompasses both experimental treatments and comparative studies with established therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.